Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jul 15

PMID 32659933

Citations 7

Authors

Cosimo Sperti

Alberto Friziero

Simone Serafini

Sergio Bissoli

Alberto Ponzoni

Andrea Grego

Emanuele Grego

Lucia Moletta

Affiliations

Soon will be listed here.

Abstract

There are currently no known preoperative factors for determining the prognosis in pancreatic cancer. The aim of this study was to examine the role of 18-fluorodeoxyglucose (18-FDG) positron emission tomography/computed tomography (18-FDG-PET/CT) as a prognostic factor for patients with resectable pancreatic cancer. Data were obtained from a retrospective analysis of patients who had a preoperative PET scan and then underwent pancreatic resection from January 2007 to December 2015. The maximum standardized uptake value (SUVmax) of 18-FDG-PET/CT was calculated. Patients were divided into high (>3.65) and low (≤3.65) SUVmax groups, and compared in terms of their TNM classification (Union for International Cancer Contro classification), pathological grade, surgical treatment, state of resection margins, lymph node involvement, age, sex, diabetes and serum Carbohydrate Antigen 19-9 (CA 19-9) levels. The study involved 144 patients, 82 with high SUVmax pancreatic cancer and 62 with low SUVmax disease. The two groups' disease-free and overall survival rates were significantly influenced by tumor stage, lymph node involvement, pathological grade, resection margins and SUVmax. Patients with an SUVmax ≤ 3.65 had a significantly better survival than those with SUVmax > 3.65 ( < 0.001). The same variables were independent predictors of survival on multivariate analysis. The SUVmax calculated with 18-FDG-PET/CT is an important prognostic factor for patients with pancreatic cancer, and may be useful in decisions concerning patients' therapeutic management.

Citing Articles

Navigating Intraductal Papillary Mucinous Neoplasm Management through Fukuoka Consensus vs. European Evidence-Based Guidelines on Pancreatic Cystic Neoplasms-A Study on Two European Centers.

Djordjevic V, Knezevic D, Trotovsek B, Tomazic A, Petric M, Hadzialjevic B Cancers (Basel). 2024; 16(11).

PMID: 38893274 PMC: 11171892. DOI: 10.3390/cancers16112156.

Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, F-FDG PET/MRI and CA 19-9.

Yoo J, Lee J, Joo I, Lee D, Yoon J, Yu M Cancer Imaging. 2023; 23(1):49.

PMID: 37217958 PMC: 10201764. DOI: 10.1186/s40644-023-00565-8.

Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.

Fiore M, Coppola A, Petrianni G, Trecca P, DErcole G, Cimini P J Gastrointest Oncol. 2023; 14(2):1114-1130.

PMID: 37201095 PMC: 10186502. DOI: 10.21037/jgo-22-1034.

Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.

Ikenaga N, Nakata K, Hayashi M, Nakamura S, Abe T, Ideno N J Gastrointest Surg. 2023; 27(2):337-346.

PMID: 36652179 DOI: 10.1007/s11605-023-05591-2.

Recent Advances in Pancreatic Neoplasms.

Sperti C, Serafini S, Moletta L J Clin Med. 2021; 10(20).

PMID: 34682848 PMC: 8540107. DOI: 10.3390/jcm10204724.

References

Nakata B, Chung Y, Nishimura S, Nishihara T, Sakurai Y, Sawada T . 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997; 79(4):695-9. View

Maisey N, Webb A, Flux G, Padhani A, Cunningham D, Ott R . FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer. 2000; 83(3):287-93. PMC: 2374572. DOI: 10.1054/bjoc.2000.1166. View

Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J . Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol. 2001; 19(1):53-8. DOI: 10.3892/ijo.19.1.53. View

Nunna P, Sheikhbahaei S, Ahn S, Young B, Subramaniam R . The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer. J Comput Assist Tomogr. 2015; 40(1):142-51. DOI: 10.1097/RCT.0000000000000323. View

Menon K, Gomez D, Smith A, Anthoney A, Verbeke C . Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009; 11(1):18-24. PMC: 2697870. DOI: 10.1111/j.1477-2574.2008.00013.x. View

Kitasato Y, Yasunaga M, Okuda K, Kinoshita H, Tanaka H, Okabe Y . Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas. Pancreas. 2014; 43(7):1060-5. PMC: 4175014. DOI: 10.1097/MPA.0000000000000185. View

Arnold M, Rutherford M, Bardot A, Ferlay J, Andersson T, Myklebust T . Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20(11):1493-1505. PMC: 6838671. DOI: 10.1016/S1470-2045(19)30456-5. View

Yamamoto T, Sugiura T, Mizuno T, Okamura Y, Aramaki T, Endo M . Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2014; 22(2):677-84. DOI: 10.1245/s10434-014-4046-2. View

Lim J, Chien M, Earle C . Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2002; 237(1):74-85. PMC: 1513971. DOI: 10.1097/00000658-200301000-00011. View

10.

Okamoto K, Koyama I, Miyazawa M, Toshimitsu Y, Aikawa M, Okada K . Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2010; 16(1):39-44. DOI: 10.1007/s10147-010-0124-z. View

11.

Ferlay J, Partensky C, Bray F . More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016; 55(9-10):1158-1160. DOI: 10.1080/0284186X.2016.1197419. View

12.

Bilici A . Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 2014; 20(31):10802-12. PMC: 4138460. DOI: 10.3748/wjg.v20.i31.10802. View

13.

Rose D, Delbeke D, Beauchamp R, Chapman W, Sandler M, Sharp K . 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999; 229(5):729-37; discussion 737-8. PMC: 1420818. DOI: 10.1097/00000658-199905000-00016. View

14.

Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P . Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2008; 24(2):175-85. DOI: 10.14670/HH-24.175. View

15.

Parlak C, Topkan E, Onal C, Reyhan M, Selek U . Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol. 2012; 7:37. PMC: 3354998. DOI: 10.1186/1748-717X-7-37. View

16.

Cloyd J, Heh V, Pawlik T, Ejaz A, Dillhoff M, Tsung A . Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020; 9(4). PMC: 7231310. DOI: 10.3390/jcm9041129. View

17.

Choi M, Heilbrun L, Venkatramanamoorthy R, Lawhorn-Crews J, Zalupski M, Shields A . Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2009; 33(3):257-61. PMC: 3848057. DOI: 10.1097/COC.0b013e3181a76a0b. View

18.

Hustinx R, Benard F, Alavi A . Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002; 32(1):35-46. DOI: 10.1053/snuc.2002.29272. View

19.

Wang L, Dong P, Wang W, Li M, Hu W, Liu X . Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2020; 99(11):e19504. PMC: 7440165. DOI: 10.1097/MD.0000000000019504. View

20.

Delbeke D, Martin W . Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001; 39(5):883-917. DOI: 10.1016/s0033-8389(05)70319-5. View